bearish
[Zai LAB (ZLAB US) Target Price Change]: Demonstrating Directionally Business Model to Profit
260 Views11 May 2023 16:10
Zai Lab (ZLAB) reported C1Q23 top line in-line with our estimate but operating/net loss much smaller than our estimate due to cut in R&D spending as well as higher interest income.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Blue Lotus Research Institute
China growth and global non-US Internet equities
- [Zai LAB (ZLAB US, SELL, TP US$20) TP Change]: Two Positive News Drove up 2024 Growth Target14 Dec 2023
- [Blue Lotus Innovative Drugs Sector Update]: Biotech-Biopharma Ecosystem Is Coming of Age in China12 Jul 2023
- [Zai LAB (ZLAB US) Target Price Change]: Demonstrating Directionally Business Model to Profit11 May 2023
- [Zai LAB (ZLAB US) Earnings Review]: Pretty Much the Same…Maintain SELL03 Mar 2023
- Zai LAB (ZLAB.US/9688.HK)：TTF Is Not a Done Deal, Both China and Globally11 Jan 2023
- Autonomous Driving- Are We There Yet?20 Mar 2018
x